<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn></journal-meta><article-meta><article-id pub-id-type="pmid">7779731</article-id><article-id pub-id-type="pmc">2033853</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Final report of a phase II study of interleukin 2 and interferon alpha in patients with metastatic melanoma.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kruit</surname><given-names>W. H.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Goey</surname><given-names>S. H.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Calabresi</surname><given-names>F.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Lindemann</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Stahel</surname><given-names>R. A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Poliwoda</surname><given-names>H.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Osterwalder</surname><given-names>B.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Stoter</surname><given-names>G.</given-names></name></contrib></contrib-group><aff>Department of Medical Oncology, Rotterdam Cancer Institute, The Netherlands.</aff><pub-date pub-type="ppub"><month>6</month><year>1995</year></pub-date><volume>71</volume><issue>6</issue><fpage>1319</fpage><lpage>1321</lpage><abstract><p>Fifty-seven patients with metastatic melanoma were treated with interleukin 2 (IL-2) 7.8 MIU m-2 day-1 as a continuous infusion for 4 days combined with interferon alpha (IFN-alpha) 6 MIU m-2 day-1 subcutaneously on days 1 and 4. The cycle was repeated every 2 weeks for a maximum number of 13 cycles. Of the 51 evaluable patients, one (2%) achieved a complete and seven (14%) a partial response (total response rate 16%; CI 7-29%). Median time to progression and median survival were 2.5 and 11.3 months respectively. This regimen of IL-2 and IFN-alpha appeared to be only moderately active.</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00052-0199.tif" xlink:title="scanned-page" xlink:role="1319" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00052-0200.tif" xlink:title="scanned-page" xlink:role="1320" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00052-0201.tif" xlink:title="scanned-page" xlink:role="1321" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

